You are here

FDA Approves Metronidazole for the Treatment of Inflammatory Lesions of Rosacea

PETALUMA, Calif., July 6 /PRNewswire/ -- Dow Pharmaceutical Sciences announced today that the US Food and Drug Administration (FDA) has approved MetroGel(R) (metronidazole) Topical Gel 1% for the topical treatment of inflammatory lesions of rosacea. This unique product was formulated, patented and developed by Dow Pharmaceutical Sciences and will be marketed in the United States through an alliance with Galderma Laboratories, a leading worldwide dermatology company.

"We are happy to be associated with a strong marketing partner like Galderma," said Dr. Bhaskar Chaudhuri, President and CEO of Dow Pharmaceutical Sciences. "Galderma's current metronidazole product line is the leading therapy for rosacea patients in the United States, and the addition of our unique formulation and strength should further enhance the success of this product line," added Dr Chaudhuri. "Galderma is one of the major companies in dermatology, and we are fortunate to have them as our marketing partner."

"We are pleased to be working with Dow Pharmaceutical Sciences," said Albert Draaijer, President of Galderma Laboratories, L.P. "This is an exciting new addition to our topical metronidazole product line," he added.

Source: Dow Pharmaceutical Sciences

Recent Headlines

Safety concerns include liver injury and interactions with other drugs
No tobacco product is safe, says the lung heath group
Discovery seen as possibly leading to new anti-TB drugs
Study points to permanent hair dye and straighteners
Score could help prevent misuse among cancer patients
'All head impacts are not the same'
How malaria parasites evade first-line drugs